Moderna, Pfizer hit with new patent lawsuits over COVID vaccines
By Blake Brittain
June 6 (Reuters) -Biotech firm Promosome LLC sued Moderna MRNA.O, Pfizer PFE.N and BioNTech 22UAy.DE, BNTX.O in federal court in San Diego, California, on Tuesday, accusing their COVID-19 vaccines of infringing a patent related to messenger RNA technology.
The lawsuits add to a web of patent disputes between biotech companies over technology used in the coronavirus shots, including a case brought last year in Massachusetts by Moderna against Pfizer and its partner BioNTech.
Promosome accused the companies of copying technology that allows for doses of mRNA that are small enough to use safely and effectively in the vaccines.
Promosome asked the court for a share of royalties from the shots. Pfizer earned $37.8 billion from sales of its COVID-19 vaccine Comirnaty last year, while Moderna made $18.4 billion from its vaccine Spikevax.
Representatives of Moderna, Pfizer and BioNTech did not immediately respond to requests for comment on the lawsuit.
Promosome attorney Bill Carmody said in a statement that the vaccine makers have "failed to give Promosome what it deserves" for creating groundbreaking technology.
San Diego and New York-based Promosome was formed to commercialize technology developed by biochemistry researchers at the Scripps Research Institute in La Jolla, California.
The vaccines use mRNA to send instructions to the immune system for producing specific proteins to fight the COVID-19 virus. Promosome said its technology enables the immune system to produce sufficient proteins to fight the virus with small doses of mRNA.
The lawsuits said Promosome met with Moderna between 2013 and 2016 to discuss licensing the technology and that Promosome's president demonstrated it to a senior BioNTech scientist in 2015. Promosome said neither company agreed to a license.
Moderna, Pfizer and BioNTech in the past have denied infringing other patents.
Reporting by Blake Brittain in Washington
Editing by David Bario and Matthew Lewis
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
